Skip to main content
Media Coverage

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush? [Microdose]

By August 28, 2025No Comments

AbbVie’s quiet acquisition of Gilgamesh Pharmaceuticals, reportedly worth close to $1 billion, did more than make headlines. It signaled something far more significant: Big Pharma has officially entered the psychedelic-adjacent chat.

Full Article >>